AbbVie to present new and updated data from 22 abstracts
PDF) Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study
Sony officially announces PSP Go
1.0 Abstract
Neuropathology of progressive supranuclear palsy after treatment with tilavonemab – Author's reply
1. Abstract
All Crohn's disease patient selection results. Abbreviations: CD,... | Download Scientific Diagram
1.0 Abstract
AbbVie's Five Biggest Priorities, Apart From Allergan :: Scrip
1.0 Abstract
Participation in an innovative patient support program reduces prescri | PPA
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial - The Lancet Neurology
ANTI-TAU TRIALS FOR ALZHEIMER'S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCE • The Journal of Prevention of Alzheimer's Disease
PSP and CBD Research
Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study - Clinical Therapeutics
Summary of Clinical Trial Results
The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares - ACR Meeting Abstracts
NCT03419403
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial | Nature Medicine
PDF) Higher Medication Adherence and Lower Opioid Use Among Individuals with Autoimmune Disease Enrolled in an Adalimumab Patient Support Program in the United States
Clinical Study Protocol M15-563 An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Incorporating Administra
Biogen Ends Trial of Its Drug for PSP - CurePSP
AbbVie Ends Tau Antibody Study - CurePSP
Summary of Clinical Trial Results
PRECLINICAL AND CLINICAL DEVELOPMENT OF ABBV-8E12, A HUMANIZED ANTI-TAU ANTIBODY, FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES • The Journal of Prevention of Alzheimer's Disease
navocaftor (GLPG3067) - Larvol Sigma
